I found this under RVX Investor documents: Plan of Arrangement On June 3, 2013, we, Zenith Epigenetics Corp. (“Zenith”, a newly incorporated company), and RVX Therapeutics Inc. (“RVX Therapeutics”) completed a Plan of Arrangement ("the Arrangement") pursuant to the Business Corporations Act (Alberta) whereby Zenith was spun out to Resverlogix shareholders. We will continue to focus on the clinical development of RVX-208, whereas Zenith through its subsidiary RVX Therapeutics will focus on drug research and development by leveraging its epigenetics platform in multiple diseases including autoimmune and oncology, excluding ApoA-I and RVX-208 technology. Upon the effective time of the Arrangement: every Resverlogix shareholder received one common share in Zenith for every common share held in Resverlogix at the effective date; Zenith owns all of the outstanding shares of RVX Therapeutics; and Zenith owns all of the outstanding royalty preferred shares of Resverlogix.